COMBINATION THERAPIES FOR TREATING CANCERS
Provided herein are methods that relate to a therapeutic strategy for treatment of cancer, including hematological malignancies. In particular, the methods include administration entospletinib and a Bcl-2 inhibitor, such as venetoclax, navitoclax, and ABT-737.
1 . A method for treating cancer in a human in need thereof, comprising administering to the human a therapeutically effective amount of a Syk inhibitor and a therapeutically effective amount of a Bcl-2 inhibitor, wherein:
the Syk inhibitor is a compound of formula A1:
or a pharmaceutically acceptable salt or hydrate thereof; and
the Bcl-2 inhibitor is selected from the group a compound of Formula B1, a compound of Formula B2, and a compound of Formula B3:
or a pharmaceutically acceptable salt thereof.
2 . The method of claim 1 , wherein the pharmaceutically acceptable salt of the Syk inhibitor is a mesylate salt, or a hydrate thereof.
3 . The method of claim 2 , wherein the mesylate salt is a mono-mesylate salt or a bis-mesylate salt, or a combination thereof.
4 . The method of claim 1 , wherein the Bcl-2 inhibitor is a compound of formula B1:
or a pharmaceutically acceptable salt thereof.
5 . The method of claim 4 wherein the compound of Formula B1 is of a form selected from the group of a free base anhydrate, a free base dichloromethane solvate, a free base ethyl acetate solvate, a free base acetonitrile solvate, a free base acetone solvate, a hydrochloride, a hydrochloride hydrate, a free base sulfate, and a free base tetrahydrofuran.
6 . The method of claim 1 , wherein the Bcl-2 inhibitor is a compound of formula B2:
or a pharmaceutically acceptable salt thereof.
7 . The method of claim 1 , wherein the Bcl-2 inhibitor is a compound of formula B3:
or a pharmaceutically acceptable salt thereof.
8 . The method of claim 7 wherein the Bcl-2 inhibitor is a bis-HCl salt of the compound of Formula B3.
9 . The method of claim 1 , wherein the Syk inhibitor is administered intravenously, intramuscularly, parenterally, nasally or orally.
10 . The method of claim 1 , wherein the Bcl-2 inhibitor is administered intravenously, intramuscularly, parenterally, nasally or orally.
11 . The method of claim 1 , wherein the Syk inhibitor is administered prior, after or concurrently with the Bcl-2 inhibitor.
12 . The method of claim 1 , wherein the cancer is a hematologic malignancy.
13 . The method of claim 1 , wherein the cancer is leukemia, lymphoma, or multiple myeloma.
14 . The method of claim 1 , wherein the cancer is small lymphocytic lymphoma, non-Hodgkin's lymphoma, indolent non-Hodgkin's lymphoma, refractory iNHL, mantle cell lymphoma, follicular lymphoma, lymphoplasmacytic lymphoma, marginal zone lymphoma, immunoblastic large cell lymphoma, lymphoblastic lymphoma, Splenic marginal zone B-cell lymphoma (+/−villous lymphocytes), Nodal marginal zone lymphoma (+/−monocytoid B-cells), extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type, cutaneous T-cell lymphoma, extranodal T-cell lymphoma, anaplastic large cell lymphoma, angioimmunoblastic T-cell lymphoma, mycosis fungoides, B-cell lymphoma, diffuse large B-cell lymphoma, Mediastinal large B-cell lymphoma, Intravascular large B-cell lymphoma, Primary effusion lymphoma, small non-cleaved cell lymphoma, Burkitt's lymphoma, multiple myeloma, plasmacytoma, acute lymphocytic leukemia, T-cell acute lymphoblastic leukemia, B-cell acute lymphoblastic leukemia, B-cell prolymphocytic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, juvenile myelomonocytic leukemia, minimal residual disease, hairy cell leukemia, primary myelofibrosis, secondary myelofibrosis, chronic myeloid leukemia, myelodysplastic syndrome, myeloproliferative disease, or Waldestrom's macroglobulinemia.
15 . The method of claim 1 in which the cancer is chronic lymphocytic leukemia.
16 . The method of claim 1 in which the cancer is acute lymphocytic leukemia.
17 . The method of claim 1 in which the cancer is non-Hodgkin's lymphoma.
18 . The method of claim 1 wherein the human is (i) refractory to at least one anti-cancer therapy, or (ii) in relapse after treatment with at least one anti-cancer therapy, or both refractory to at least one anti-cancer therapy and in relapse after treatment with at least one anti-cancer therapy.
19 . A kit comprising:
(i) a pharmaceutical composition comprising a therapeutically effective amount of a Syk inhibitor, wherein the Syk inhibitor is a compound of Formula A1:
or a pharmaceutically acceptable salt or hydrate thereof;
(ii) a pharmaceutical composition comprising a therapeutically effective amount of a Bcl-2 inhibitor, wherein the Bcl-2 inhibitor is selected from the group of a compound of Formula B1, a compound of Formula B2, and a compound of Formula B3:
or a pharmaceutically acceptable salt thereof.
20 . The kit of claim 12 , further comprising a package insert containing instructions for use of the pharmaceutical compositions in treating a cancer.